Opus Point Partners Management’s ProQR Therapeutics PRQR Stock Holding History

Opus Point Partners Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$798K	Hold	138,461	–	–	1.44%	15
2019 Q2	$1.26M	Hold	138,461	–	–	1.86%	10
2019 Q1	$1.92M	Hold	138,461	–	–	2.6%	5
2018 Q4	$2.19M	Hold	138,461	–	–	4.81%	4
2018 Q3	$2.68M	Sell	138,461 -15,385	-10%	-$164K	6.4%	2
2018 Q2	$1.12M	Hold	153,846	–	–	2.44%	15
2018 Q1	$473K	Sell	153,846 -153,846	-50%	-$495K	0.93%	30
2017 Q4	$992K	Buy	+307,692	New	+$1.1M	0.86%	35

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Opus Point Partners Management's PRQR Position: Q3 2019 in Review

Opus Point Partners Management held its ProQR Therapeutics (PRQR) position steady in Q3 2019 at 138,461 shares worth $798K. The position accounts for 1.44% of the portfolio, ranked #15.

Opus Point Partners Management first reported a position in PRQR in Q4 2017 and has held it in 8 quarters since. The position peaked at $2.68M in Q3 2018. 50 funds tracked by Wall St. Rank hold PRQR as of Q3 2019.

Opus Point Partners Management held 138,461 shares of ProQR Therapeutics worth $798K as of Q3 2019.
Opus Point Partners Management left its ProQR Therapeutics share count unchanged in Q3 2019.
ProQR Therapeutics made up 1.44% of Opus Point Partners Management's portfolio in Q3 2019, its #15 holding.
Opus Point Partners Management first reported a position in ProQR Therapeutics in Q4 2017 and has held it in 8 quarters since.
Opus Point Partners Management's ProQR Therapeutics position peaked at $2.68M in Q3 2018.
50 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.